Hematopoietic Stem/Progenitor Cell Product Thawing

• Use cryopreserved HPC product bags or vials containing peripheral blood stem/progenitor cells, cord blood cells, bone marrow HPCs, or expanded cord-blood CD34+ HSPCs;
• Use dextran/albumin-containing dilution or wash buffer for cord-blood thaw/wash procedures when following the reported 1:1 initial dilution approach;
• Use validated wash solutions or automated-system compatible wash buffers when performing DMSO reduction, because studies assessed CD34+ recovery, TNC recovery, viability, CFU recovery, osmolarity reduction, and DMSO elimination after such processing.

• Retrieve the cryopreserved HPC product and prepare the post-thaw processing path before thawing, because published workflows evaluate either direct post-thaw samples, thaw-and-dilute procedures, or thaw-wash/concentration procedures and compare cell recovery, viability, DMSO reduction, and progenitor function after processing.

• Prepare flow-cytometry and functional testing aliquots before product manipulation so that post-thaw and post-wash samples can be compared for TNC recovery, viable CD34+ recovery, viability, CD3+ or CD45+ recovery where relevant, and CFU activity.

• Thaw the cryopreserved HPC product rapidly at 37°C, then proceed immediately to the selected literature-supported pathway: for cord-blood grafts, perform an initial 1:1 dilution using a dextran/albumin-containing buffer before washing;
• For autologous peripheral-blood HPC products, process thawed cells through an automated closed wash system when DMSO removal is the experimental goal;
• For expanded cord-blood HSPCs, apply either thaw-and-dilute or rinse-based thawing only as reported in the comparative thawing study.

• For automated washing or concentration, collect samples after thawing and after washing, then quantify TNCs, viable CD34+ cells, viability, and CFU activity;
• Studies reported high CD34+ recovery after automated cord-blood washing, median viable TNC recovery of 89%, viable CD34+ recovery of 103%, CFU recovery of 91%, and DMSO elimination of 98% in one automated HPC-apheresis washing study, and 97% average DMSO removal with maintained CD34+ viability and stability up to 6 hours in a Lovo-based study.

• For direct comparison of wash versus no-wash strategies, compare post-thaw aliquots with post-wash aliquots and record infusion-related adverse reactions only in clinical-use studies;
• One automated Sepax wash study reported no significant loss of CD34+ cell count or viability after washing and fewer infusion-related adverse reactions compared with prior non-washed infusions.

• Analyze post-thaw product quality by viable CD34+ cell recovery, TNC recovery, viability, and CFU activity, because these endpoints were repeatedly used to assess whether thawing, dilution, washing, or cryopreservation conditions preserved graft quality and progenitor function.

• Interpret CD34+ percentages carefully after thawing because one study found that the percentage of CD34+ cells may increase after cryopreservation due to loss of other cell populations, while the absolute viable CD34+ cell number remained the more relevant recovery endpoint.

• When processing multiple bags or delayed infusions, evaluate stability under the reported post-processing window rather than assuming unlimited stability;
• One Lovo study reported maintained CD34+ viability and stability up to 6 hours, and one Sepax-2 reproducibility study reported comparable intra-batch and inter-batch CD34+ recovery and CD45+ viability after automated concentration of thawed HPC products.

Low viable CD34+ recovery after thawing or washing:

Possible Cause
Product-intrinsic quality factors and pre-cryopreservation variables can affect downstream recovery.
Solution
Measure paired pre- and post-processing CD34+ recovery and viability, and treat low recovery as a batch/product-quality finding rather than correcting it with unsupported handling changes; Sepax-2 reproducibility data indicated that lower recoveries tended to recur across batches from the same product.

Infusion-related adverse reactions after thawed HPC product administration:

Possible Cause
DMSO and other post-thaw product components are implicated in adverse reactions.
Solution
Use validated post-thaw washing or DMSO-reduction workflows when clinically indicated, because automated washing studies reported substantial DMSO removal and reduced infusion-related adverse reactions while preserving CD34+ recovery and viability.

Apparent increase in CD34+ percentage after thawing:

Possible Cause
Preferential loss of non-CD34+ cells can increase the CD34+ percentage without increasing the absolute viable CD34+ dose.
Solution
Report absolute viable CD34+ cell recovery in addition to CD34+ percentage.